Vaccine in Biological Technology
Navigation Links
Vaccine in Biological Technology
Novavax Reports Second Quarter 2009 Financial Results
... first quarter, Novavax continued to advance its vaccine pipeline, improved its balance sheet by raising ... season influenza virus-like-particle ("VLP") vaccine candidate. The company is planning on reporting ... to ROVI to create a comprehensive influenza vaccine solution including a facility for the Spanish ...Microbix Sales Grow 22% For Nine Months
... over our traditional markets." Influenza vaccine Business "Influenza vaccine has been in the news since the emergence of the ... Gastle. "There is a global capacity shortage of vaccine supply as ...GenVec Reports Second Quarter 2009 Financial Results
... continues to make strides in its therapeutic and vaccine programs. We look forward to sharing additional ... with Cobra BioManufacturing. vaccine Programs GenVec expanded an existing contract with the PATH Malaria vaccine Initiative (MVI) to support the development of ...PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
... recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim((R)) -- a fully human monoclonal ... RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information ...GeoVax Labs, Inc. Provides Clinical Studies Update
... Bulletin Board: GOVX), an Atlanta-based HIV/AIDS vaccine development company, today announced updates on ... "We have two main areas of focus for our HIV/AIDS vaccine - preventative and therapeutic," stated Robert ... clinical work for the preventative version of the vaccine have allowed the company to move up to another ...ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
... ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with ... "Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into ... Technologies continues to strengthen its vaccine pipeline through licensing and strategic ...Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
... the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine and, during the three day observation period, the ... tests indicated that the A/H1N1 influenza vaccine is safe and reliable in humans. The ...Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
... that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, ... A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans. The ...... recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human ... RypVax(TM) - a recombinant dual antigen vaccine for plague For more information ...
... has achieved additional positive results with its vaccine candidate for the Influenza A (H1N1) virus, also ... 100% of vaccinated animals. Medicago's H1N1 VLP vaccine was formulated to protect against the influenza ... original viral strains selected by the WHO for vaccine manufacturers. The Company previously reported ...
First genetically engineered malaria vaccine to enter human trials
... the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in ... and Immunity division, said in developing the vaccine the research team had deleted two key genes in ... malaria infection. He said it was hoped the vaccine would produce similar results in humans. ...Sanofi-aventis Announces Second Quarter 2009 Results
... for the quarter includes $32.5 million of H5N1 vaccine sales in the United States, against $192.5 million in the second quarter of 2008. Excluding H5N1 vaccine sales, second-quarter sales were up 18.4%. In the ... ((R)) (the first 5-in-1 pediatric combination vaccine licensed in the United States in June 2008 ...FluMist(R) Begins Shipping for 2009-2010 Influenza Season
... that it has begun shipping its seasonal influenza vaccine FluMist((R) )(Influenza vaccine Live, Intranasal) to vaccine distributors who service health care providers ...GenVec Expands Contract Supporting Malaria Vaccine Program
... of an existing contract with the PATH Malaria vaccine Initiative (MVI) to support the development of ... USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated ... (PATH): www.path.org PATH Malaria vaccine Initiative: www.malariavaccine.org ...Vi typhoid vaccine proves highly effective in young children
... found that a currently available yet underused vaccine against typhoid fever is highly effective in ... The study, conducted by the International vaccine Institute (IVI) in collaboration with the ... percent lower risk of typhoid, indicating that Vi vaccine conferred substantial herd protection. The ...Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
... viron vaccine with adjuvant, and whole viron vaccine with adjuvant, will be tested in the trial. ... trial is to provide scientific evidence for the vaccine formulation and dosage through ... developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional ...... selection of a Respiratory Syncytial Virus (RSV) vaccine candidate that will be advanced into additional ... Novavax has been evaluating a number of RSV vaccine candidates, all of which have successfully ... Novavax scientists have now engineered a new vaccine candidate which has been shown to protect mice ...
... Mr. Trizzino was Vice President of the vaccine franchise at MedImmune, Inc., Senior Vice ... experience with the last 12 years focused on the vaccine and biotech market. He has managed a number of important flu vaccine products, including FluMist and Fluviral ...
ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
... - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has entered into an ... our antigens become part of such an innovative vaccine candidate," said Ramila Philip, president and CSO ... of Immunotope agreement. DPX-0907 is a novel vaccine because of its potential to create a depot at the ...... and deliver up to 25 million doses of an rPA vaccine for the Strategic National Stockpile, as ... generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection. This product employs modern vaccine technology to provide a highly purified and well ...
Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
... and sell products such as seasonal influenza vaccine and potentially other novel vaccines against ... based on Novavax's virus-like-particle (VLP) vaccine technology. CPL Biologicals also expects to develop the pandemic H1N1 influenza vaccine candidate in India that Novavax is developing in ...CEL-SCI Corporation Releases Letter to Shareholders
... and other influenza viruses, as well as a vaccine for rheumatoid arthritis. 2) Unique contract ... development of the therapeutic and preventative vaccine approaches that our scientists have pioneered. ... the therapeutic and longer-term preventative vaccine approaches we are investigating could address ...GeoVax Labs, Inc. Announces Resignation of Director
... Bulletin Board: GOVX), an Atlanta-based HIV/AIDS vaccine development company, announced today that Mr. ... and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed ... with AIDS virus). GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet ...Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain
... recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) ... technology to create a comprehensive influenza vaccine solution for the Spanish government under a new ... exclusive licenses to Novavax's portable VLP vaccine technology to commercialize flu vaccines in Spain ...Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply
... - The CDC Reinstates Booster Dose of Hib vaccine - SWIFTWATER, Pa., June 25 /PRNewswire/ -- ... dose of Haemophilus influenzae type b (Hib) vaccine after 12 months of age. The CDC also provided ... a temporary deferral of the booster dose of Hib vaccine in 2007 due to supply constraints caused by ...... Trivalent Virus-Like Particle vaccine Elicits Protective Immune Responses against a ... development of the company's investigational VLP vaccine against the H3N2, H1N1 and B influenza strains. ... from the University of Pittsburgh , Center for vaccine Research and Novavax, was published in the June ...
... for their use world-wide either as an injected vaccine before a person is infected or exposed or as a therapeutic vaccine for treatment." Experimental work has ... that vaccines utilizing the L.E.A.P.S. vaccine technology with specificity for particular ...
Sinovac Receives China's First Influenza A (H1N1) Vaccine Order
... order in China to supply its influenza A (H1N1) vaccine to the Beijing government. The initial ... and production abilities from both the H5N1 vaccine and seasonal flu vaccine to ensure the efficient production of the H1N1 ...GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
... It will also assist in accelerating GeoVax's vaccine program for treatment of patients infected with ... be focused on accelerating GeoVax's therapeutic vaccine program for treatment of individuals already ... would bear responsibility for production of the vaccine supply, establishment, management and oversight ...Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
... Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, ... Officer, will be presenting at the Phacilitate vaccine Forum Barcelona 2009 conference on June 22 and ... results, results of our seasonal influenza vaccine or any ...Sinovac Completes Construction of H1N1 Virus Seed Bank
... Production of Seasonal Influenza vaccine Is Nearly Completed BEIJING, June 15 ... (CDC) on June 8, 2009 and started the H1N1 vaccine production on the same day. Sinovac expects to ... batch and initiate clinical trials of an H1N1 vaccine by the end of July 2009. Mr. Weidong Yin, ...Commercial Manufacturing of H1N1 'Swine Flu' Vaccine Underway
... that today it commenced manufacturing of a vaccine to protect humans against the H1N1 "swine flu" ... PSC believes that PanBlok is the first and only vaccine that could be used to protect against the ... few months. Following bulk production, the vaccine will undergo routine quality tests, the longest ...... responses to the concomitantly administered vaccine and showed a safety profile comparable to ... including Prevenar. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a ... Prevenar does not provide 100% protection against vaccine serotypes or protect against ...
... This is cause for concern and an accelerated vaccine effort." For both the Infectivity Gene and ... genes have been inhibited by the Two-Punch(TM) vaccine system -- designed to be concurrently directed at ... a Two-Punch(TM) PanFlu(TM) vaccine. The same vaccine system has been successfully tested against H5N1 ...
Sinovac Begins the Production of Influenza A (H1N1) Vaccine
... today that it begins the production of a vaccine against influenza A (H1N1) virus. The virus seed ... virus seed, we will start the production of H1N1 vaccine immediately from production of virus seed ... Panflu, Sinovac's pandemic influenza vaccine with H1N1 virus seed upon approval from ...... steps towards producing Influenza A (H1N1) VLP vaccine for animal and human testing ROCKVILLE, Md., ... in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for ...
... MedImmune Plans to Begin Shipping Seasonal vaccine to Health Care Providers in August ... (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1) to vaccinate ... Influenza. An initial order of $90 million of vaccine has been placed, with the potential for ...
... headline data with our prostate cancer vaccine candidate, PROSTVAC(TM), ready to start Phase 3 ... PROSTVAC(TM) PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that ... is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts ...
Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
... understanding how this virus performs in a vaccine manufacturing environment and developing a ... agencies. Sanofi Pasteur operates influenza vaccine production facilities in Swiftwater, Pa. and Val ... Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than ...AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
... and Parkinson's disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS ... call. The supported project - known as CETP vaccine (ETB-2008-28) - is based on the AFFITOME(R) ... the concentration of the beneficial HDL. This vaccine approach with its long-lasting effects should ...Other ContentshydrocelehydatidiformhydrocephalushymenhyperactivityhyperactivityhyperactivityhyperactivityhypercalcemiaOther TagsBeatBeatUGAUGAUGAUGAUGAapeapeapeapeapeapeapeslightsavesfoldfoldfoldOther Tagssight 2sight 3sight 4sight 5sight 6blocked 2blocked 3blocked 4blocked 5blocked 6blocked 7blocked 8blocked 9blocked 10impact 2impact 3impact 4impact 5impact 6impact 7impact 8impact 9impact 10double 2double 3double 4double 5double 6double 7double 8double 9double 10segment 2segment 3segment 4segment 5connecting 2cultured 2cultured 3cultured 4cultured 5cultured 6cultured 7
(Date:12/4/2009)... the total gene activity in organs relevant for coronary ... Karolinska Institutet have identified a module of genes that ... into the atherosclerotic plaque. The findings, which are to ... , suggest that targeting the migration of white blood ...
(Date:12/4/2009)... release is available in German . , ... of Ageing could help to understand the positive effect of ... (fruit flies and mice) have shown that dietary restriction increases ... fertility. So the female fruit fly reproduces less frequently with ...
(Date:12/3/2009)... Dec. 3 BIO-key International, Inc. (OTC Bulletin ... and finger-based biometric identification solutions, announced that a ... Meeting held today approved the sale of the ... Inc. Of the shares voted, 98.6% were cast ...
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How nutrition affects healthy aging 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3The ends of mRNAs may prevent the beginnings of cancer 9638 1The ends of mRNAs may prevent the beginnings of cancer 9638 2ESCO Announces Major Contract Award for Its Thermoforming Business 54966 1ESCO Announces Major Contract Award for Its Thermoforming Business 54966 2Lost Hikers Backpackers Really Do Walk in Circles 54961 1Lost Hikers Backpackers Really Do Walk in Circles 54961 2Lost Hikers Backpackers Really Do Walk in Circles 54961 3(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Onyx Pharmaceuticals, ... safety data from the pivotal Phase 2b 003-A1 ... carfilzomib is well-tolerated in heavily pre-treated relapsed and ... today at the ASH/ASCO Joint Symposium at the ... Hematology (ASH) in New Orleans. Enrollment in this ...
(Date:12/6/2009)... Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... with herbal or natural sleep aids from around ... for a good cause. The submissions will be ... Aids ,Encyclopedia, by YOU, to be sold from ... will donate 100% of the proceeds ,from sales ...
(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...
(Date:12/5/2009)... myeloproliferative disorders are serious and often deadly blood ... Meeting of the American Society of Hematology introduces ... for patients suffering from acute promyelocytic leukemia, chronic ... that are based on a better understanding of ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2[1] Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability[0] Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You [0] New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer[0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders[0] AVIVA's Private Health Insurance Products Solutions Go International
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |